Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards

AstraZeneca Sheds Rights to Three Respiratory Drugs for $350M

By Mike Botta | November 7, 2018

(Image credit: Shutterstock)

AstraZeneca has agreed to sell rights outside the U.S. for respiratory drugs Alvesco, Omnaris, and Zetonna to Zug, Switzerland-based Covis Pharma B.V., which acquired the U.S. rights for the drugs in 2017. Covis will become the owner of the medicines upon closing. 

Covis Pharma will pay AstraZeneca $350 million in addition to conditional sales-related payments of up to $21 million over four years starting in 2019. AstraZeneca had reported that 2017 combined product sales of Alvesco, Omnaris, and Zetonna were $106 million.

Alvesco is an inhaled anti-inflammatory maintenance therapy delivered by a metered-dose inhaler to help control persistent asthma. 

Omnaris and Zetonna are nasal sprays for the treatment of symptoms associated with seasonal allergic and allergic/non-allergic perennial rhinitis, an inflammation and swelling of the mucous membrane of the nose, characterized by a runny nose and stuffiness.

The active ingredient in all three medicines is ciclesonide, a synthetic corticosteroid that helps relieve inflammation.

Mark Mallon, AstraZeneca’s executive VP of global product and portfolio strategy, said the move is in line with company divestment objectives to shed parts of its portfolio in order to allocate resources toward developing  new medicines that address unmet patient needs.

The transaction does not include the transfer of any AstraZeneca employees or facilities. Completion of the agreement is expected by year end.

(Source: AstraZeneca)

Related Articles Read More >

A Zipline fixed-wing drone in the air drops a package
Cardinal Health starts Zipline drone deliveries of drugs and medical supplies
Pfizer logo
Pfizer to spend $120M to make COVID-19 oral treatment in U.S.
Image of MedTrace Pharma's P3 automated delivery system for 15-O water in action
MedTrace Pharma moves forward on 15 O-water imaging tech
coronavirus COVID-19 Pfizer
NIH starts evaluating second COVID-19 booster shots in adults

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Pharmaceutical Processing World
  • Subscribe to Our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • R&D 100 Awards